RedHill Biopharma Ltd. received approval from Brazil’s health regulator for its global Phase 2/3 study, which evaluates its proprietary inhibitor called opaganib in …
The objective of any investor is a simple one: to make money. While this objective couldn’t be clearer, it is much harder putting …
In a research report released today, Roth Capital analyst Scott Henry reiterated a Buy rating on RedHill Biopharma (NASDAQ:RDHL) with a $27.50 price …